N/A
Completed N=39
FREEZE-AFIB Post-Market Study
Source: ClinicalTrials.gov NCT05089877 ↗Enrolled (actual)
39
Serious AEs
36.4%
Results posted
Jan 2025
Primary outcomePrimary: Freedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events. — 0 Participants
Summary
This study is proposed herein is to gather clinical data on the safety and performance of the CRYOF device.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Freedom From Death, Stroke (Regardless of Level of Disability), Myocardial Infarction, and Major Bleeding Events. |
— | — |
| PRIMARY Freedom From Any Documented AF, AFL or AT Lasting >30 Seconds in the Duration of the Last Follow-up Visit Off Antiarrhythmic Therapy (Except of AADs at Doses Not Exceeding Those Previously Failed |
25 | — |
| SECONDARY Freedom From Any Documented AF, AFL, or AT Lasting >30 Seconds at the Last Follow-up Visit Regardless of Class I or III AADs |
— | — |
| SECONDARY Freedom From Any Documented AF, AFL, or AT Lasting >30 Seconds at the Last Follow-up Visit in the Absence of Class I or III AADs. |
— | — |
| SECONDARY Acute Procedural Success Defined as Documentation of Sinus Rhythm at the End of the Procedure. |
— | — |
Eligibility Criteria
Inclusion Criteria
- Subject is greater than or equal to 18 years of age.
- Subject has documented history of atrial fibrillation.
- Subjects who received surgical ablation for their atrial fibrillation using CRYOF and on whom at least the following lesions were performed: Left and right pulmonary vein isolation, roof and floor lines, mitral annulus line and a connecting lesion from left atrial appendage to left pulmonary vein coronary sinus lesion and LAA exclusion , with a lesion duration of at least 2 minutes.
- Stable subject that underwent non-emergent cardiac surgical procedure(s) on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, or coronary artery bypass procedures, or atrial septal defect (ASD) repair
- Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 90 days of enrollment as documented in patient medical history).
- Subject is willing and able to provide written informed consent.
- Subject is willing and able to return for scheduled follow-up visits.
Exclusion Criteria
- Stand-alone AF without indication(s) for concomitant CABG and/or valve surgery.
- Previous left sided ablation procedures procedure.
- Untreated atrial flutter and symptomatic ventricular arrythmia
- Known carotid artery stenosis greater than 80% prior to index ablation procedure.
- Prior history of ischemic stroke or hemorrhagic stroke
- History of MI with ST elevation within 6 weeks prior to the index ablation
- Documented AF duration of greater than 10 years.
- Large left atrial size i.e., LA diameter >7 cm prior to the index ablation procedure.
- Subjects with active systemic infection prior to index ablation procedure.
- Subjects who had documented severe peripheral arterial occlusive disease defined as claudication with minimal exertion prior to the ablation procedure.
- Subjects with history of renal failure requiring dialysis or hepatic failure prior to the ablation procedure.
- A known drug and/or alcohol addiction.
- Mental impairment or other conditions which may not allow the subject to understand the nature, significance, and scope of the study.
- Subjects who are pregnant
- Subjects who had preoperative need for mechanical circulatory support or intravenous inotropes.
- Subjects who are on anti-arrhythmic drug therapy for the treatment of another arrhythmia.
- Subjects in currently undergoing chemotherapy.
- Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases).
- Subjects who had known connective tissue disorders at the time of index ablation procedure
- Subjects who had known hypertrophic obstructive cardiomyopathy at the time of index ablation procedure
- Subjects with known cold agglutinin.
- Subjects who had or tested positive for COVID-19
- Subjects with bleeding disorders and/or inability to receive anticoagulation
- Subjects undergoing aortic dissection surgery as index procedure.
- Cardiac surgical re-intervention since the index cardiac surgery with concomitant AF ablation procedure
Data sourced from ClinicalTrials.gov (NCT05089877). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.